Notching on cancer's door: Notch signaling in brain tumors

Frontiers in Oncology

Volumn 4, Issue NOV, 2014, Pages

  Teodorczyk, Marcin ^a   Schmidt, Mirko H H ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Brain tumor therapy; Clinical trials; Glioma; Medulloblastoma; Notch signaling; Stem like brain tumor propagating cells

Indexed keywords

ANKYRIN; ANTIBODY; CD133 ANTIGEN; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR 1; DELTA LIKE 1 PROTEIN; DELTA LIKE 3 PROTEIN; DELTA LIKE 4 PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR LIKE PROTEIN 7; GAMMA SECRETASE INHIBITOR; GLIAL FIBRILLARY ACIDIC PROTEIN; HISTONE ACETYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE BINDING PROTEIN; JAGGED1; JAGGED2; MEMBRANE PROTEIN; MYC PROTEIN; NOTCH RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SMALL INTERFERING RNA; TENASCIN; TRANSCRIPTION FACTOR MASH1; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR SOX2; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR DECOY RECEPTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BRAIN TUMOR; CANCER GROWTH; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM; DOWN REGULATION; EMBRYO DEVELOPMENT; GENE OVEREXPRESSION; GENOME; GLIA CELL; GLIOMA; HUMAN; INTRACELLULAR SIGNALING; MAMMAL; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTNATAL DEVELOPMENT; RECURRENT DISEASE; REGULATORY MECHANISM; REVIEW; SURVIVAL; TUMOR INVASION;

EID: 84915823465     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00341     Document Type: Review

References (193)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica (2007) 114(2):97-109. doi: 10.1007/s00401-007-0243-4.
2. Wen PY, Kesari S. Malignant gliomas in adults. The New England journal of medicine (2008) 359(5):492-507. doi: 10.1056/NEJMra0708126.
3. Bralten LB, French PJ. Genetic alterations in glioma. Cancers (2011) 3(1):1129-40. doi:10.3390/cancers3011129.
4. Yoshida J. Molecular neurosurgery using gene therapy to treat malignant glioma. Nagoya journal of medical science (1996) 59(3-4):97-105.
5. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, et al. Riskadapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma- 96): long-term results from a prospective, multicentre trial. The lancet oncology (2006) 7(10):813-20. doi: 10.1016/S1470-2045(06)70867-1.
6. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine (2005) 352(10):987-96. doi: 10.1056/NEJMoa043330.
7. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 455(7216):1061-8. doi:10.1038/nature07385.
8. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 321(5897):1807-12. doi: 10.1126/science.1164382.
9. Teodorczyk M, Martin-Villalba A. Sensing invasion: cell surface receptors driving spreading of glioblastoma. Journal of cellular physiology (2010) 222(1):1-10. doi:10.1002/jcp.21901.
10. Blaumueller CM, Qi H, Zagouras P, Artavanis-Tsakonas S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell (1997) 90(2):281-91.
11. Rebay I, Fleming RJ, Fehon RG, Cherbas L, Cherbas P, Artavanis-Tsakonas S. Specific EGF repeats of Notch mediate interactions with Delta and Serrate: implications for Notch as a multifunctional receptor. Cell (1991) 67(4):687-99.
12. del Amo FF, Gendron-Maguire M, Swiatek PJ, Jenkins NA, Copeland NG, Gridley T. Cloning, analysis, and chromosomal localization of Notch-1, a mouse homolog of Drosophila Notch. Genomics (1993) 15(2):259-64. doi: 10.1006/geno.1993.1055.
13. Weinmaster G, Roberts VJ, Lemke G. Notch2: a second mammalian Notch gene. Development (1992) 116(4):931-41.
14. Lardelli M, Dahlstrand J, Lendahl U. The novel Notch homologue mouse Notch 3 lacks specific epidermal growth factor-repeats and is expressed in proliferating neuroepithelium. Mechanisms of development (1994) 46(2):123-36.
15. Uyttendaele H, Marazzi G, Wu G, Yan Q, Sassoon D, Kitajewski J. Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development (1996) 122(7):2251-9.
16. Aster JC, Simms WB, Zavala-Ruiz Z, Patriub V, North CL, Blacklow SC. The folding and structural integrity of the first LIN-12 module of human Notch1 are calciumdependent. Biochemistry (1999) 38(15):4736-42. doi: 10.1021/bi982713o.
17. Sanchez-Irizarry C, Carpenter AC, Weng AP, Pear WS, Aster JC, Blacklow SC. Notch subunit heterodimerization and prevention of ligand-independent proteolytic activation depend, respectively, on a novel domain and the LNR repeats. Molecular and cellular biology (2004) 24(21):9265-73. doi: 10.1128/MCB.24.21.9265-9273.2004.
18. Gordon WR, Vardar-Ulu D, Histen G, Sanchez-Irizarry C, Aster JC, Blacklow SC. Structural basis for autoinhibition of Notch. Nature structural & molecular biology (2007) 14(4):295-300. doi: 10.1038/nsmb1227.
19. Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ, et al. A ligandinduced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Molecular cell (2000) 5(2):197-206.
20. Tamura K, Taniguchi Y, Minoguchi S, Sakai T, Tun T, Furukawa T, et al. Physical interaction between a novel domain of the receptor Notch and the transcription factor RBP-J kappa/Su(H). Current biology: CB (1995) 5(12):1416-23.
21. Lubman OY, Korolev SV, Kopan R. Anchoring notch genetics and biochemistry; structural analysis of the ankyrin domain sheds light on existing data. Molecular cell (2004) 13(5):619-26.
22. Lieber T, Kidd S, Alcamo E, Corbin V, Young MW. Antineurogenic phenotypes induced by truncated Notch proteins indicate a role in signal transduction and may point to a novel function for Notch in nuclei. Genes & development (1993) 7(10):1949-65.
23. Kurooka H, Kuroda K, Honjo T. Roles of the ankyrin repeats and C-terminal region of the mouse notch1 intracellular region. Nucleic acids research (1998) 26(23):5448-55.
24. Rechsteiner M. Regulation of enzyme levels by proteolysis: the role of pest regions. Advances in enzyme regulation (1988) 27:135-51.
25. Bettenhausen B, Hrabe de Angelis M, Simon D, Guenet JL, Gossler A. Transient and restricted expression during mouse embryogenesis of Dll1, a murine gene closely related to Drosophila Delta. Development (1995) 121(8):2407-18.
26. Dunwoodie SL, Henrique D, Harrison SM, Beddington RS. Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo. Development (1997) 124(16):3065-76.
27. Shutter JR, Scully S, Fan W, Richards WG, Kitajewski J, Deblandre GA, et al. Dll4, a novel Notch ligand expressed in arterial endothelium. Genes & development (2000) 14(11):1313-8.
28. Lindsell CE, Shawber CJ, Boulter J, Weinmaster G. Jagged: a mammalian ligand that activates Notch1. Cell (1995) 80(6):909-17.
29. Shawber C, Boulter J, Lindsell CE, Weinmaster G. Jagged2: a serrate-like gene expressed during rat embryogenesis. Developmental biology (1996) 180(1):370-6. doi: 10.1006/dbio.1996.0310.
30. Parks AL, Stout JR, Shepard SB, Klueg KM, Dos Santos AA, Parody TR, et al. Structure-function analysis of delta trafficking, receptor binding and signaling in Drosophila. Genetics (2006) 174(4):1947-61. doi: 10.1534/genetics.106.061630.
31. Shimizu K, Chiba S, Kumano K, Hosoya N, Takahashi T, Kanda Y, et al. Mouse jagged1 physically interacts with notch2 and other notch receptors. Assessment by quantitative methods. The Journal of biological chemistry (1999) 274(46):32961-9.
32. Hu QD, Ang BT, Karsak M, Hu WP, Cui XY, Duka T, et al. F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation. Cell (2003) 115(2):163-75.
33. D'Souza B, Meloty-Kapella L, Weinmaster G. Canonical and non-canonical Notch ligands. Current topics in developmental biology (2010) 92:73-129. doi:10.1016/S0070-2153(10)92003-6.
34. Schmidt MH, Bicker F, Nikolic I, Meister J, Babuke T, Picuric S, et al. Epidermal growth factor-like domain 7 (EGFL7) modulates Notch signalling and affects neural stem cell renewal. Nature cell biology (2009) 11(7):873-80. doi: 10.1038/ncb1896.
35. Meister J, Schmidt MH. miR-126 and miR-126*: new players in cancer. The Scientific World Journal (2010) 10:2090-100. doi: 10.1100/tsw.2010.198.
36. Dikic I, Schmidt MH. Notch: Implications of endogenous inhibitors for therapy. BioEssays: news and reviews in molecular, cellular and developmental biology (2010) 32(6):481-7. doi: 10.1002/bies.200900140.
37. de Celis JF, Bray S. Feed-back mechanisms affecting Notch activation at the dorsoventral boundary in the Drosophila wing. Development (1997) 124(17):3241-51.
38. Li Y, Baker NE. The roles of cis-inactivation by Notch ligands and of neuralized during eye and bristle patterning in Drosophila. BMC developmental biology (2004) 4:5. doi:10.1186/1471-213X-4-5.
39. Miller AC, Lyons EL, Herman TG. cis-Inhibition of Notch by endogenous Delta biases the outcome of lateral inhibition. Current biology: CB (2009) 19(16):1378-83. doi:10.1016/j.cub.2009.06.042.
40. Cordle J, Johnson S, Tay JZ, Roversi P, Wilkin MB, de Madrid BH, et al. A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cisinhibition. Nature structural & molecular biology (2008) 15(8):849-57. doi:10.1038/nsmb.1457.
41. Zolkiewska A. ADAM proteases: ligand processing and modulation of the Notch pathway. Cellular and molecular life sciences: CMLS (2008) 65(13):2056-68. doi:10.1007/s00018-008-7586-4.
42. Glomski K, Monette S, Manova K, De Strooper B, Saftig P, Blobel CP. Deletion of Adam10 in endothelial cells leads to defects in organ-specific vascular structures. Blood (2011) 118(4):1163-74. doi: 10.1182/blood-2011-04-348557.
43. Weber S, Niessen MT, Prox J, Lullmann-Rauch R, Schmitz A, Schwanbeck R, et al. The disintegrin/metalloproteinase Adam10 is essential for epidermal integrity and Notch-mediated signaling. Development (2011) 138(3):495-505. doi:10.1242/dev.055210.
44. Bozkulak EC, Weinmaster G. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Molecular and cellular biology (2009) 29(21):5679-95. doi:10.1128/MCB.00406-09.
45. Weber S, Saftig P. Ectodomain shedding and ADAMs in development. Development (2012) 139(20):3693-709. doi: 10.1242/dev.076398.
46. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature (1999) 398(6727):518-22. doi: 10.1038/19083.
47. Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nature genetics (2000) 26(4):484-9. doi: 10.1038/82644.
48. Wallberg AE, Neely KE, Hassan AH, Gustafsson JA, Workman JL, Wright AP. Recruitment of the SWI-SNF chromatin remodeling complex as a mechanism of gene activation by the glucocorticoid receptor tau1 activation domain. Molecular and cellular biology (2000) 20(6):2004-13.
49. Kurooka H, Honjo T. Functional interaction between the mouse notch1 intracellular region and histone acetyltransferases PCAF and GCN5. The Journal of biological chemistry (2000) 275(22):17211-20. doi: 10.1074/jbc. M000909200.
50. Iso T, Sartorelli V, Chung G, Shichinohe T, Kedes L, Hamamori Y. HERP, a new primary target of Notch regulated by ligand binding. Molecular and cellular biology (2001) 21(17):6071-9.
51. Iso T, Sartorelli V, Poizat C, Iezzi S, Wu HY, Chung G, et al. HERP, a novel heterodimer partner of HES/E(spl) in Notch signaling. Molecular and cellular biology (2001) 21(17):6080-9.
52. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signalling downstream of activated mammalian Notch. Nature (1995) 377(6547):355-8. doi:10.1038/377355a0.
53. Fischer A, Gessler M. Delta-Notch--and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic acids research (2007) 35(14):4583-96. doi: 10.1093/nar/gkm477.
54. Kageyama R, Ohtsuka T. The Notch-Hes pathway in mammalian neural development. Cell research (1999) 9(3):179-88. doi: 10.1038/sj.cr.7290016.
55. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. Journal of cellular physiology (2003) 194(3):237-55. doi:10.1002/jcp.10208.
56. Cheng P, Zlobin A, Volgina V, Gottipati S, Osborne B, Simel EJ, et al. Notch-1 regulates NF-kappaB activity in hemopoietic progenitor cells. Journal of immunology (2001) 167(8):4458-67.
57. Oswald F, Liptay S, Adler G, Schmid RM. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Molecular and cellular biology (1998) 18(4):2077-88.
58. NickoloffBJ, Qin JZ, Chaturvedi V, Denning MF, Bonish B, Miele L. Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. Cell death and differentiation (2002) 9(8):842-55. doi: 10.1038/sj.cdd.4401036.
59. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proceedings of the National Academy of Sciences of the United States of America (2006) 103(48):18261-6. doi: 10.1073/pnas.0606108103.
60. Sharma VM, Calvo JA, Draheim KM, Cunningham LA, Hermance N, Beverly L, et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of cmyc. Molecular and cellular biology (2006) 26(21):8022-31. doi: 10.1128/MCB.01091-06.
61. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, et al. c- Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes & development (2006) 20(15):2096-109. doi:10.1101/gad.1450406.
62. Ehm O, Goritz C, Covic M, Schaffner I, Schwarz TJ, Karaca E, et al. RBPJkappadependent signaling is essential for long-term maintenance of neural stem cells in the adult hippocampus. The Journal of neuroscience: the official journal of the Society for Neuroscience (2010) 30(41):13794-807. doi: 10.1523/JNEUROSCI.1567-10.2010.
63. Kumar JP, Moses K. EGF receptor and Notch signaling act upstream of Eyeless/Pax6 to control eye specification. Cell (2001) 104(5):687-97.
64. Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Molecular and cellular biology (2001) 21(17):5925-34.
65. Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. The EMBO journal (2001) 20(13):3427-36. doi:10.1093/emboj/20.13.3427.
66. Beatus P, Lendahl U. Notch and neurogenesis. Journal of neuroscience research (1998) 54(2):125-36.
67. Lasky JL, Wu H. Notch signaling, brain development, and human disease. Pediatric research (2005) 57(5 Pt 2):104R-9R. doi: 10.1203/01.PDR.0000159632.70510.3D.
68. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science (1999) 284(5415):770-6.
69. Bray SJ. Notch signalling: a simple pathway becomes complex. Nature reviews Molecular cell biology (2006) 7(9):678-89. doi: 10.1038/nrm2009.
70. Gaiano N, Fishell G. The role of notch in promoting glial and neural stem cell fates. Annual review of neuroscience (2002) 25:471-90. doi:10.1146/annurev.neuro.25.030702.130823.
71. Wang S, Barres BA. Up a notch: instructing gliogenesis. Neuron (2000) 27(2):197-200.
72. Bicker F, Schmidt MH. EGFL7: a new player in homeostasis of the nervous system. Cell cycle (2010) 9(7):1263-9.
73. de la Pompa JL, Wakeham A, Correia KM, Samper E, Brown S, Aguilera RJ, et al. Conservation of the Notch signalling pathway in mammalian neurogenesis. Development (1997) 124(6):1139-48.
74. Swiatek PJ, Lindsell CE, del Amo FF, Weinmaster G, Gridley T. Notch1 is essential for postimplantation development in mice. Genes & development (1994) 8(6):707-19.
75. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell (1991) 66(4):649-61.
76. Ntziachristos P, Lim JS, Sage J, Aifantis I. From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer cell (2014) 25(3):318-34. doi:10.1016/j.ccr.2014.02.018.
77. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer research (2004) 64(21):7787-93. doi: 10.1158/0008-5472.CAN-04-1446.
78. Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou MF, Ionescu MC, et al. Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer research (2009) 69(2):458-65. doi: 10.1158/0008-5472.CAN-08-2610.
79. Cheung HC, Corley LJ, Fuller GN, McCutcheon IE, Cote GJ. Polypyrimidine tract binding protein and Notch1 are independently re-expressed in glioma. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc (2006) 19(8):1034-41. doi: 10.1038/modpathol.3800635.
80. Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer research (2005) 65(6):2353-63. doi: 10.1158/0008-5472.CAN-04-1890.
81. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer cell (2006) 9(3):157-73. doi:10.1016/j.ccr.2006.02.019.
82. Li J, Cui Y, Gao G, Zhao Z, Zhang H, Wang X. Notch1 is an independent prognostic factor for patients with glioma. Journal of surgical oncology (2011) 103(8):813-7. doi:10.1002/jso.21851.
83. Xu P, Yu S, Jiang R, Kang C, Wang G, Jiang H, et al. Differential expression of Notch family members in astrocytomas and medulloblastomas. Pathology oncology research: POR (2009) 15(4):703-10. doi: 10.1007/s12253-009-9173-x.
84. Boulay JL, Miserez AR, Zweifel C, Sivasankaran B, Kana V, Ghaffari A, et al. Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PloS one (2007) 2(6):e576. doi: 10.1371/journal.pone.0000576.
85. Castro DS, Skowronska-Krawczyk D, Armant O, Donaldson IJ, Parras C, Hunt C, et al. Proneural bHLH and Brn proteins coregulate a neurogenic program through cooperative binding to a conserved DNA motif. Developmental cell (2006) 11(6):831-44. doi:10.1016/j.devcel.2006.10.006.
86. Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S, et al. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene (2005) 24(47):7073-83. doi:10.1038/sj.onc.1208865.
87. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell (2010) 17(1):98-110. doi: 10.1016/j.ccr.2009.12.020.
88. Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L, et al. Contribution of Notch signaling activation to human glioblastoma multiforme. Journal of neurosurgery (2007) 106(3):417-27. doi: 10.3171/jns.2007.106.3.417.
89. Zhang XP, Zheng G, Zou L, Liu HL, Hou LH, Zhou P, et al. Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Molecular and cellular biochemistry (2008) 307(1-2):101-8. doi: 10.1007/s11010-007-9589-0.
90. Koutelou E, Sato S, Tomomori-Sato C, Florens L, Swanson SK, Washburn MP, et al. Neuralized-like 1 (Neurl1) targeted to the plasma membrane by N-myristoylation regulates the Notch ligand Jagged1. The Journal of biological chemistry (2008) 283(7):3846-53. doi: 10.1074/jbc. M706974200.
91. Nakamura H, Yoshida M, Tsuiki H, Ito K, Ueno M, Nakao M, et al. Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region. Oncogene (1998) 16(8):1009-19. doi:10.1038/sj.onc.1201618.
92. Teider N, Scott DK, Neiss A, Weeraratne SD, Amani VM, Wang Y, et al. Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. Neurooncology (2010) 12(12):1244-56. doi: 10.1093/neuonc/noq091.
93. McGill MA, McGlade CJ. Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. The Journal of biological chemistry (2003) 278(25):23196-203. doi: 10.1074/jbc. M302827200.
94. Qiu L, Joazeiro C, Fang N, Wang HY, Elly C, Altman Y, et al. Recognition and ubiquitination of Notch by Itch, a hect-type E3 ubiquitin ligase. The Journal of biological chemistry (2000) 275(46):35734-7. doi: 10.1074/jbc. M007300200.
95. Nie J, McGill MA, Dermer M, Dho SE, Wolting CD, McGlade CJ. LNX functions as a RING type E3 ubiquitin ligase that targets the cell fate determinant Numb for ubiquitindependent degradation. The EMBO journal (2002) 21(1-2):93-102. doi:10.1093/emboj/21.1.93.
96. Chen J, Xu J, Zhao W, Hu G, Cheng H, Kang Y, et al. Characterization of human LNX, a novel ligand of Numb protein X that is downregulated in human gliomas. The international journal of biochemistry & cell biology (2005) 37(11):2273-83. doi:10.1016/j.biocel.2005.02.028.
97. Hulleman E, Quarto M, Vernell R, Masserdotti G, Colli E, Kros JM, et al. A role for the transcription factor HEY1 in glioblastoma. Journal of cellular and molecular medicine (2009) 13(1):136-46. doi: 10.1111/j.1582-4934.2008.00307.x.
98. Gaetani P, Hulleman E, Levi D, Quarto M, Scorsetti M, Helins K, et al. Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study. Tumori (2010) 96(1):97-102.
99. Yin D, Xie D, Sakajiri S, Miller CW, Zhu H, Popoviciu ML, et al. DLK1: increased expression in gliomas and associated with oncogenic activities. Oncogene (2006) 25(13):1852-61. doi: 10.1038/sj.onc.1209219.
100. Xu P, Zhang A, Jiang R, Qiu M, Kang C, Jia Z, et al. The different role of Notch1 and Notch2 in astrocytic gliomas. PloS one (2013) 8(1):e53654. doi:10.1371/journal.pone.0053654.
101. Leins A, Riva P, Lindstedt R, DavidoffMS, Mehraein P, Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer (2003) 98(11):2430-9. doi: 10.1002/cncr.11796.
102. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes & development (2012) 26(8):756-84. doi: 10.1101/gad.187922.112.
103. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer cell (2002) 1(3):269-77.
104. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 455(7216):1129-33. doi: 10.1038/nature07443.
105. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer cell (2005) 8(2):119-30. doi: 10.1016/j.ccr.2005.07.004.
106. Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell (2011) 146(2):209-21. doi: 10.1016/j.cell.2011.06.014.
107. Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, et al. Non-stem cell origin for oligodendroglioma. Cancer cell (2010) 18(6):669-82. doi:10.1016/j.ccr.2010.10.033.
108. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes & development (2001) 15(15):1913-25. doi: 10.1101/gad.903001.
109. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer research (2006) 66(19):9339-44. doi: 10.1158/0008-5472.CAN-06-3126.
110. Jordan CT. Cancer stem cells: controversial or just misunderstood? Cell stem cell (2009) 4(3):203-5. doi: 10.1016/j.stem.2009.02.003.
111. Li Y, Laterra J. Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer research (2012) 72(3):576-80. doi: 10.1158/0008-5472.CAN-11-3070.
112. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature (2004) 432(7015):396-401. doi:10.1038/nature03128.
113. Bayin NS, Modrek AS, Placantonakis DG. Glioblastoma stem cells: Molecular characteristics and therapeutic implications. World journal of stem cells (2014) 6(2):230-8. doi: 10.4252/wjsc.v6.i2.230.
114. Christensen K, Schroder HD, Kristensen BW. CD133+ niches and single cells in glioblastoma have different phenotypes. Journal of neuro-oncology (2011) 104(1):129-43. doi: 10.1007/s11060-010-0488-y.
115. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science (2007) 317(5836):337. doi: 10.1126/science.1142596.
116. Pfenninger CV, Roschupkina T, Hertwig F, Kottwitz D, Englund E, Bengzon J, et al. CD133 is not present on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells, and glioblastoma cells. Cancer research (2007) 67(12):5727-36. doi: 10.1158/0008-5472.CAN-07-0183.
117. Christensen K, Schroder HD, Kristensen BW. CD133 identifies perivascular niches in grade II-IV astrocytomas. Journal of neuro-oncology (2008) 90(2):157-70. doi:10.1007/s11060-008-9648-8.
118. Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell (2012) 149(1):36-47. doi: 10.1016/j.cell.2012.03.009.
119. Shih AH, Holland EC. Notch signaling enhances nestin expression in gliomas. Neoplasia (2006) 8(12):1072-82. doi: 10.1593/neo.06526.
120. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer cell (2007) 11(1):69-82. doi:10.1016/j.ccr.2006.11.020.
121. Dahlrot RH, Hermansen SK, Hansen S, Kristensen BW. What is the clinical value of cancer stem cell markers in gliomas? International journal of clinical and experimental pathology (2013) 6(3):334-48.
122. Hitoshi S, Alexson T, Tropepe V, Donoviel D, Elia AJ, Nye JS, et al. Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes & development (2002) 16(7):846-58. doi: 10.1101/gad.975202.
123. Morrison SJ, Perez SE, Qiao Z, Verdi JM, Hicks C, Weinmaster G, et al. Transient Notch activation initiates an irreversible switch from neurogenesis to gliogenesis by neural crest stem cells. Cell (2000) 101(5):499-510.
124. Solecki DJ, Liu XL, Tomoda T, Fang Y, Hatten ME. Activated Notch2 signaling inhibits differentiation of cerebellar granule neuron precursors by maintaining proliferation. Neuron (2001) 31(4):557-68.
125. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer cell (2006) 9(5):391-403. doi: 10.1016/j.ccr.2006.03.030.
126. Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene (2008) 27(20):2897-909. doi:10.1038/sj.onc.1210949.
127. Guichet PO, GuelfiS, Teigell M, Hoppe L, Bakalara N, Bauchet L, et al. Notch1 stimulation induces a vascularization switch with pericyte-like cell differentiation of glioblastoma stem cells. Stem cells (2014). doi: 10.1002/stem.1767.
128. Jiang X, Xing H, Kim TM, Jung Y, Huang W, Yang HW, et al. Numb regulates glioma stem cell fate and growth by altering epidermal growth factor receptor and Skp1-Cullin- F-box ubiquitin ligase activity. Stem cells (2012) 30(7):1313-26. doi:10.1002/stem.1120.
129. Kargiotis O, Rao JS, Kyritsis AP. Mechanisms of angiogenesis in gliomas. Journal of neuro-oncology (2006) 78(3):281-93. doi: 10.1007/s11060-005-9097-6.
130. Poellinger L, Lendahl U. Modulating Notch signaling by pathway-intrinsic and pathway-extrinsic mechanisms. Current opinion in genetics & development (2008) 18(5):449-54. doi: 10.1016/j.gde.2008.07.013.
131. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. The American journal of pathology (2010) 177(3):1491-502. doi:10.2353/ajpath.2010.091021.
132. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Developmental cell (2005) 9(5):617-28. doi: 10.1016/j.devcel.2005.09.010.
133. Pistollato F, Rampazzo E, Persano L, Abbadi S, Frasson C, Denaro L, et al. Interaction of hypoxia-inducible factor-1alpha and Notch signaling regulates medulloblastoma precursor proliferation and fate. Stem cells (2010) 28(11):1918-29. doi:10.1002/stem.518.
134. Qiang L, Wu T, Zhang HW, Lu N, Hu R, Wang YJ, et al. HIF-1alpha is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell death and differentiation (2012) 19(2):284-94. doi: 10.1038/cdd.2011.95.
135. Hu YY, Fu LA, Li SZ, Chen Y, Li JC, Han J, et al. Hif-1alpha and Hif-2alpha differentially regulate Notch signaling through competitive interaction with the intracellular domain of Notch receptors in glioma stem cells. Cancer letters (2014) 349(1):67-76. doi: 10.1016/j.canlet.2014.03.035.
136. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. Journal of neuropathology and experimental neurology (1998) 57(7):684-9.
137. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proceedings of the National Academy of Sciences of the United States of America (1987) 84(19):6899-903.
138. Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Current cancer drug targets (2012) 12(3):197-209.
139. Aguirre A, Rubio ME, Gallo V. Notch and EGFR pathway interaction regulates neural stem cell number and self-renewal. Nature (2010) 467(7313):323-7. doi:10.1038/nature09347.
140. Kuhn HG, Winkler J, Kempermann G, Thal LJ, Gage FH. Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. The Journal of neuroscience: the official journal of the Society for Neuroscience (1997) 17(15):5820-9.
141. Ayuso-Sacido A, Moliterno JA, Kratovac S, Kapoor GS, O'Rourke DM, Holland EC, et al. Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. Journal of neuro-oncology (2010) 97(3):323-37. doi: 10.1007/s11060-009-0035-x.
142. Purow BW, Sundaresan TK, Burdick MJ, Kefas BA, Comeau LD, Hawkinson MP, et al. Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis (2008) 29(5):918-25. doi: 10.1093/carcin/bgn079.
143. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Molecular cell (2003) 12(4):889-901.
144. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 444(7120):756-60. doi: 10.1038/nature05236.
145. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Molecular cancer (2006) 5:67. doi: 10.1186/1476-4598-5-67.
146. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem cells (2010) 28(1):5-16. doi: 10.1002/stem.254.
147. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer research (2006) 66(15):7445-52. doi: 10.1158/0008-5472.CAN-06-0858.
148. Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer research (2004) 64(21):7794-800. doi: 10.1158/0008-5472.CAN-04-1813.
149. Lewis SJ, Smith AL, Neduvelil JG, Stevenson GI, Lindon MJ, Jones AB, et al. A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core. Bioorganic & medicinal chemistry letters (2005) 15(2):373-8. doi:10.1016/j.bmcl.2004.10.062.
150. Gilbert CA, Daou MC, Moser RP, Ross AH. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer research (2010) 70(17):6870-9. doi: 10.1158/0008-5472.CAN-10-1378.
151. Hiddingh L, Tannous BA, Teng J, Tops B, Jeuken J, Hulleman E, et al. EFEMP1 induces gamma-secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget (2014) 5(2):363-74.
152. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, et al. Notch promotes radioresistance of glioma stem cells. Stem cells (2010) 28(1):17-28. doi:10.1002/stem.261.
153. Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, et al. A high Notch pathway activation predicts response to gamma secretase inhibitors in proneural subtype of glioma tumorinitiating cells. Stem cells (2014) 32(1):301-12. doi: 10.1002/stem.1528.
154. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology (2012) 30(19):2348-53. doi: 10.1200/JCO.2011.36.8282.
155. Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, et al. A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). British journal of cancer (2013) 109(4):943-9. doi:10.1038/bjc.2013.380.
156. Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, et al. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Investigational new drugs (2014) 32(2):243-9. doi: 10.1007/s10637-013-9965-4.
157. Diaz-Padilla I, Hirte H, Oza AM, Clarke BA, Cohen B, Reedjik M, et al. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Investigational new drugs (2013) 31(5):1182-91. doi: 10.1007/s10637-013-0001-5.
158. Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, et al. A phase II study of RO4929097 in metastatic colorectal cancer. European journal of cancer (2012) 48(7):997-1003. doi: 10.1016/j.ejca.2012.02.056.
159. De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, Dasari A, et al. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Investigational new drugs (2014) 32(4):739-45. doi: 10.1007/s10637-014-0083-8.
160. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology (2012) 30(19):2307-13. doi: 10.1200/JCO.2011.39.1540.
161. Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology (2011) 29(26):3529-34. doi: 10.1200/JCO.2011.35.7806.
162. Beel AJ, Sanders CR. Substrate specificity of gamma-secretase and other intramembrane proteases. Cellular and molecular life sciences: CMLS (2008) 65(9):1311-34. doi: 10.1007/s00018-008-7462-2.
163. Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS biology (2008) 6(10):e257. doi:10.1371/journal.pbio.0060257.
164. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. The Journal of biological chemistry (2004) 279(13):12876-82. doi: 10.1074/jbc. M311652200.
165. Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. Current topics in medicinal chemistry (2008) 8(1):54-61.
166. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicological sciences: an official journal of the Society of Toxicology (2004) 82(1):341-58. doi: 10.1093/toxsci/kfh254.
167. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, et al. Gammasecretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nature medicine (2009) 15(1):50-8. doi: 10.1038/nm.1900.
168. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 444(7122):1083-7. doi: 10.1038/nature05313.
169. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, et al. Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 464(7291):1052-7. doi:10.1038/nature08878.
170. Aste-Amezaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, et al. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PloS one (2010) 5(2):e9094. doi: 10.1371/journal.pone.0009094.
171. Li K, Li Y, Wu W, Gordon WR, Chang DW, Lu M, et al. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. The Journal of biological chemistry (2008) 283(12):8046-54. doi:10.1074/jbc. M800170200.
172. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature (2006) 444(7122):1032-7. doi: 10.1038/nature05355.
173. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer research (2007) 67(23):11244-53. doi: 10.1158/0008-5472.CAN-07-0969.
174. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer research (2011) 71(18):6073-83. doi: 10.1158/0008-5472.CAN-11-1704.
175. Jenkins DW, Ross S, Veldman-Jones M, Foltz IN, Clavette BC, Manchulenko K, et al. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Molecular cancer therapeutics (2012) 11(8):1650-60. doi: 10.1158/1535-7163.MCT-11-1027.
176. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature (2010) 463(7282):E6-7. doi:10.1038/nature08751.
177. Poirault-Chassac S, Six E, Catelain C, Lavergne M, Villeval JL, Vainchenker W, et al. Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation. Blood (2010) 116(25):5670-8. doi: 10.1182/blood-2010-05-285957.
178. Funahashi Y, Hernandez SL, Das I, Ahn A, Huang J, Vorontchikhina M, et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer research (2008) 68(12):4727-35. doi: 10.1158/0008-5472.CAN-07-6499.
179. Hernandez SL, Banerjee D, Garcia A, Kangsamaksin T, Cheng WY, Anastassiou D, et al. Notch and VEGF pathways play distinct but complementary roles in tumor angiogenesis. Vascular cell (2013) 5(1):17. doi: 10.1186/2045-824X-5-17.
180. Varnum-Finney B, Wu L, Yu M, Brashem-Stein C, Staats S, Flowers D, et al. Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. Journal of cell science (2000) 113 Pt 23:4313-8.
181. Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R, et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood (2007) 109(11):4753-60. doi: 10.1182/blood-2006-12-063933.
182. Small D, Kovalenko D, Kacer D, Liaw L, Landriscina M, Di Serio C, et al. Soluble Jagged 1 represses the function of its transmembrane form to induce the formation of the Src-dependent chord-like phenotype. The Journal of biological chemistry (2001) 276(34):32022-30. doi: 10.1074/jbc. M100933200.
183. Six E, Ndiaye D, Laabi Y, Brou C, Gupta-Rossi N, Israel A, et al. The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and gamma-secretase. Proceedings of the National Academy of Sciences of the United States of America (2003) 100(13):7638-43. doi: 10.1073/pnas.1230693100.
184. Nichol D, Shawber C, Fitch MJ, Bambino K, Sharma A, Kitajewski J, et al. Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7. Blood (2010) 116(26):6133-43. doi: 10.1182/blood-2010-03-274860.
185. Johnson L, Huseni M, Smyczek T, Lima A, Yeung S, Cheng JH, et al. Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. The Journal of clinical investigation (2013) 123(9):3997-4009. doi: 10.1172/JCI67892.
186. Huang C, Yuan X, Li Z, Tian Z, Zhan X, Zhang J, et al. VE-statin/Egfl7 siRNA inhibits angiogenesis in malignant glioma in vitro. International journal of clinical and experimental pathology (2014) 7(3):1077-84.
187. Li Y, Zhang J, Ma D, Zhang L, Si M, Yin H, et al. Curcumin inhibits proliferation and invasion of osteosarcoma cells through inactivation of Notch-1 signaling. The FEBS journal (2012) 279(12):2247-59. doi: 10.1111/j.1742-4658.2012.08607.x.
188. Lee WH, Loo CY, Bebawy M, Luk F, Mason RS, Rohanizadeh R. Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Current neuropharmacology (2013) 11(4):338-78. doi: 10.2174/1570159X11311040002.
189. Lim KJ, Bisht S, Bar EE, Maitra A, Eberhart CG. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer biology & therapy (2011) 11(5):464-73.
190. Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacology & therapeutics (2013) 139(2):95-110. doi: 10.1016/j.pharmthera.2013.02.003.
191. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, et al. Direct inhibition of the NOTCH transcription factor complex. Nature (2009) 462(7270):182-8. doi: 10.1038/nature08543.
192. Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, et al. Mutant KRAS is a druggable target for pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America (2013) 110(51):20723-8. doi: 10.1073/pnas.1314307110.
193. Mamaeva V, Rosenholm JM, Bate-Eya LT, Bergman L, Peuhu E, Duchanoy A, et al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Molecular therapy: the journal of the American Society of Gene Therapy (2011) 19(8):1538-46. doi: 10.1038/mt.2011.105.